🟢 Eli Lilly is trading 8% up today after raising 2026 revenue outlook

Eli Lilly is trading at $1392.02, up 8.05%, after strong demand for Mounjaro and Zepbound drove third-quarter results.

• On October 29, 2026, Eli Lilly reported third-quarter revenue of $24.4 billion, beating estimates, and raised its 2026 revenue outlook to $91 billion–$92 billion from $85 billion–$87 billion.
• Adjusted EPS outlook was lowered to $35–$36 after $4.57 per share in acquired R&D charges; Foundayo sales missed analyst forecasts, offsetting the positive results.